42例直肠超声引导经皮氩氦冷冻治疗中晚期前列腺癌

目的 探讨氩氦冷冻治疗中晚期前列腺癌的有效性和安全性.方法 回顾性分析42例采用直肠超声引导,经皮氩氦冷冻治疗的中晚期前列腺癌(C、D期)患者的临床资料.患者冷冻治疗后1-12个月检测前列腺特异抗原(PSA)1次/月,并于治疗后3、6、12个月随访患者前列腺体积、最大尿流率(MFR)、生化无进展生存率(bPFS)、PSA缓解率、肿瘤复发情况等,据此进行疗效评价.结果 采用重复测量方差分析.结果 冷冻治疗前及治疗后3、6、12个月,PSA分别为(4.48±1.35)、(3.54±1.67)、(3.18±1.76)、(2.87±1.89)lug/L;前列腺体积分别为(59.7±8.2)、(46.9±8.3)、(26.2±3.9)、(25.9±3.7)mm3;MFB分别为(10.4±0.8)、(14.3±1.2)、(18.3±1.3)、(18.9±1.3)ml/s,治疗前后差异均有统计学意义(F值分别为53.93、747.92、3843.03,P值均<0.01).治疗后3、6、12个月bPFS分别为95.2%(40/42)、95.2%(40/42)、90.5%(38/42).根据PSA缓解率,治疗后12个月总有效率73.8%(31/42,完全缓解16例、部分缓解15例),稳定16.7%(7/42),进展9.5%(4/42).本组治疗后出现一过性尿失禁、阴茎感觉异常、阴囊水肿各1例,会阴部疼痛2例,无重症感染、出血、尿道直肠瘘等严重并发症发生.结论 氩氦冷冻治疗中晚期前列腺癌近期效果满意.

Percutaneous cryoabladon of prostate cancer guided by rectal ultrasound: a retrospectively analysis of 42 cases

Objective To evaluate the effectiveness and safety of rectal ultrasound-guided agon- hilium percutaneous cryoablation in treatment of patients with median and or late-stage prostate cancer patients. Methods Retrospectively analysis of 42 cases of with stage C and D prostate cancer patients treated by rectal ultrasound-guided argon&ilium percutaneous cryoablation during the follow-up of 1--12 months. The prostate specific antigen (PSA), biochemical progression-free survival (bPFS), PSA objective response, transrectal ultrasound of the prostate (TRUS), TRUS-guided biopsy of the prostate, the maximum urinary flow rate(MFR), MRI examination at before, and 3,6,12 months after cryoablatian were recorded and evaluated. The results were statistically evaluated by using variance analysis. Results The PSA value at before and 3, 6, 12 months after cryoablation were (4.48±1.35), (3.54±1.67), (3.18±1.76), (2.87±1.89) ug/L, respectively; TRUS-messured prostate volumes at before and 3, 6,12 months after cryoablation were (59.7± 8.2),(46.9±8.3),(26.2±3.9),(25.9±3.7)mm3, respectively; MFR before and 3, 6,12 months after cryoablation were (10.4±0.8), (14.3±1.2), (18.3±1.3), (18.9±1.3) ml/s, respectively; Compared with before cryoablation, the differences between before and after cryoablation was statistically significant( F = 53.93,747.92,3843.03,respectively, P<0.01). The bPFS rates in 3 months,6 months and 12 months were 95.2% (40/42), 95. 2% (40/42), and 90.5% (38/42), respectively. According to the PSA response, the total effective rate (CR 16 cases, PR 15 cases) at 12 months was 73. 8%, and SD was 16.7% (7/42), PD was 9.5% (4/42). Complications included temporary incontinence 2.4% (1/42), Penile tingling/numbness 2.4% (1/42), pelvic pain 4.9% (2/41) and Scrotum Edema 2.4% (1/42). There was no case with severe complications such as severe infection or urethrorectal fistula, etc. Condusions Rectal ultrasound-guided agon-hilium percutaneous cryoablation showed is a well tolerated and has better early clinical efficacy to the treatment of stage C and D prostate cancer.